Research Topics
| Donna Pauler AnkerstSummaryAffiliation: University of Texas Health Science Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Understanding mixed messages about prostate specific antigen: biases in the evaluation of cancer biomarkersDonna Pauler Ankerst
J Urol 177:426-7. 2007- New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancerDonna Pauler Ankerst
Dept of Urology, University of Texas Health Science Center at San Antonio, San Antonio, USA
Arch Ital Urol Androl 78:154-6. 2006..e., there is an ascertainment bias. We are currently performing a quantitative investigation of whether or not this ascertainment bias could explain the higher number of high-grade disease cases observed on the finasteride arm... 
Yearly prostate specific antigen and digital rectal examination fluctuations in a screened populationDonna Pauler Ankerst
Depatment of Urology, University of Texas Health Sciences Center, San Antonio, Texas, USA
J Urol 181:2071-5; discussion 2076. 2009..Prostate biopsy is often recommended based on increases in prostate specific antigen and/or abnormal digital rectal examination. We investigated the stability of a single positive test during the next 3 consecutive years...- Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative GroupDonna P Ankerst
Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229, USA
World J Urol 30:181-7. 2012.... - Trends and co-trends of prostate-specific antigen and body mass index in a screened populationDonna P Ankerst
Department of Urology, University of Texas, Health Science Center at San Antonio, San Antonio, TX 78229, USA
Urology 78:10-6. 2011..This report investigated whether annual changes in body mass index (BMI) are associated with the opposite changes in prostate-specific antigen (PSA). Previous studies have confirmed lower PSA levels among men with higher BMI... - Predicting prostate cancer risk through incorporation of prostate cancer gene 3Donna Pauler Ankerst
Department of Urology, University of Texas Health Sciences Center, San Antonio, Texas 78229, USA
J Urol 180:1303-8; discussion 1308. 2008..In this report we incorporate the biomarker prostate cancer gene 3 into the Prostate Cancer Prevention Trial risk calculator... - Effect of finasteride on the sensitivity of PSA for detecting prostate cancerIan M Thompson
Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
J Natl Cancer Inst 98:1128-33. 2006..We examined the impact of finasteride on the sensitivity and area under the receiver operating characteristic curve (AUC) of prostate-specific antigen (PSA) for detecting prostate cancer... - Assessment of 54 biomarkers for biopsy-detectable prostate cancerDipen J Parekh
Department of Urology, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284 7802, USA
Cancer Epidemiol Biomarkers Prev 16:1966-72. 2007.... - Assessing prostate cancer risk: results from the Prostate Cancer Prevention TrialIan M Thompson
Department of Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA
J Natl Cancer Inst 98:529-34. 2006..We used prostate biopsy data from men who participated in the Prostate Cancer Prevention Trial (PCPT) to develop a predictive model of prostate cancer... - Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mLEdith Canby Hagino
Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
Urology 70:748-52. 2007..We assessed the risk of prostate cancer in men with a positive family history (at least one first-degree or second-degree relative), normal digital rectal examination (DRE) and a serum prostate-specific antigen (PSA) level of 4.0 ng/mL... - Total prostate specific antigen stability confirmed after long-term storage of serum at -80CAmanda Beth Reed
Department of Urology, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas
J Urol 180:534-7; discussion 537-8. 2008..We characterized the long-term stability of total prostate specific antigen in serum samples after storage at -80C from 2001 until 2007... - Biomarkers for prostate cancer detectionDipen J Parekh
Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284 7802, USA
J Urol 178:2252-9. 2007..New markers that differentiate indolent from aggressive cancers to decrease potential the over treatment of prostate cancer are needed. We reviewed current and potential biomarkers for prostate cancer detection... - External validation of the Prostate Cancer Prevention Trial risk calculator in a screened populationDipen J Parekh
Department of Urology, University of Texas Health Science Center, San Antonio, Texas 78229, USA
Urology 68:1152-5. 2006.... - Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verificationDonna Pauler Ankerst
Dept of Urology, University of Texas Health Science Center at San Antonio, San Antonio, USA
Arch Ital Urol Androl 78:125-9. 2006..Lowering the PSA threshold for screening increases detection of aggressive cancer at an earlier stage, but has the unavoidable tradeoff of increased detection of the biologically irrelevant cancers... - Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lowerIan M Thompson
Department of Urology, University of Texas Health Science Center at San Antonio, TX 78229, USA
JAMA 294:66-70. 2005..Three fourths of US men older than 50 years have been screened with prostate-specific antigen (PSA) for prostate cancer... - Merging digital rectal exam, family history, age and prostate-specific antigen to create a decision-making toolDonna Pauler Ankerst
Dept of Urology, University of Texas Health Science Center at San Antonio, San Antonio, USA
Arch Ital Urol Androl 78:143-6. 2006..Similarly, age, which is also a predictor of prostate cancer in the absence of other factors, did not add independent prognostic information to PSA, DRE, family history, and prior biopsy... - Obesity, adipokines, and prostate cancer in a prospective population-based studyJacques Baillargeon
Center for Epidemiology and Biostatistics, University of Texas Health Sciences Center at San Antonio, 78284 7802, USA
Cancer Epidemiol Biomarkers Prev 15:1331-5. 2006..The purpose of this investigation was to examine the association of obesity and the adipokines leptin, adiponectin, and interleukin-6 (IL-6) with prostate cancer risk and aggressiveness... - Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention TrialCarol M Moinpour
Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center M3 C102, 1100 Fairview Ave North, Box 19024, Seattle, WA 98109 1024, USA
J Natl Cancer Inst 99:1025-35. 2007..The PCPT offered an opportunity to prospectively study the effects of finasteride and other covariates on sexual dysfunction... - Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16Daniel P Petrylak
Columbia University, New York, NY 10032, USA
J Natl Cancer Inst 98:516-21. 2006..We evaluated PSA changes as potential surrogate markers for survival by using data from a clinical trial... - The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysisStefan Boeck
Department of Internal Medicine III, Klinikum Grosshadern, Munich, Germany
Oncology 72:314-21. 2007..The role of adjuvant treatment strategies (including chemotherapy and chemoradiotherapy) following resection of pancreatic cancer remains controversial... - Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisoneDonna L Berry
University of Washington, Seattle, WA 98195 7266, USA
J Clin Oncol 24:2828-35. 2006..While Southwest Oncology Group trial 99-16 demonstrated a survival improvement of DE over MP, the study also was designed to compare the palliation of disease-related symptoms...